Request Demo

Last update 08 May 2025

Guangzhou Baiyunshan Xing Zhu Pharmacentical Co., Ltd.

Subsidiary Company|2013|Guangdong Sheng, China

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

100 Clinical Results associated with Guangzhou Baiyunshan Xing Zhu Pharmacentical Co., Ltd.

0 Patents (Medical) associated with Guangzhou Baiyunshan Xing Zhu Pharmacentical Co., Ltd.

Literatures (Medical) associated with Guangzhou Baiyunshan Xing Zhu Pharmacentical Co., Ltd.

Guangzhou Zhongyiyao Daxue Xuebao

Content Determination of Baicalin from Radix Scutellariae Herbal Materials and Decoction Residues and In Vitro Antibacterial Activity

Author: Dai Bi-xin ; Dong Bi-lian ; Zhu Sheng-shan ; Cai Yan-qu

Objective To determine the content of baicalin from Radix Scutellariae herbal materials and decoction residues, and to explore the in vitro antibacterial effect of baicalin.Methods UV-spectrophotometry was used to determine the content of baicalin from herbal materials, decoction residues 1(compounds extracting), and decoction residues 2(single herb extracting)of Radix Scutellariae.The double dilution method and paper method were used to determine the min. inhibitory concentration(MIC)of herbal materials, decoction residues 1, and decoction residues 2 of Radix Scutellariae against the Vibrio parahaemolyticus, Escherichia coli, Klebsiella pneumoniae, and their diameter of the inhibition zone.Results The content of baicalin from herbal materials, decoction residues 1, and decoction residues 2 of Radix Scutellariae was 4.91%, 2.05%, 2.25%, resp.;the min. inhibitory concentration of Radix Scutellariae herbal materials against Vibrio parahaemolyticus, Escherichia coli and Klebsiella pneumoniae was 0.98, 3.91, 62.5 mg/mL, and the diameter of the inhibition zone was 17.5, 15.5, 9.0 mm, resp.;the min. inhibitory concentration of Radix Scutellariae decoction residues 1 against Vibrio parahaemolyticus, Escherichia coli and Klebsiella pneumoniae was 31.25, 125, >250 mg/mL, and the diameter of the inhibition zone was 11.0, 0, 0 mm, resp.; the min. inhibitory concentration of Radix Scutellariae decoction residues 2 against Vibrio parahaemolyticus, Escherichia coli and Klebsiella pneumoniae were 31.25, >250, >250 mg/mL, and the diameter of the inhibition zone was 10.0, 0, 0 mm, resp.;the min. inhibitory concentration of the pos. control drug Chinese herbal compound NZ against Vibrio parahaemolyticus, Escherichia coli and Klebsiella pneumoniae was 0.24, 1.95, 31.25 mg/mL, and the inhibition zone diameter was 22.0, 22.0, 21.0 mm, resp.Conclusion The content and MIC value of baicalin between from Radix Scutellariae compounds extracting decoction residues and from Radix Scutellariae single herb extracting decoction residues are not significantly different, and the decoction residues have better utilization value with baicalin content as the index.The MIC values of the two decoction residues against different strains are significantly different, and the difference reaches 39 times that of the original herb.

100 Deals associated with Guangzhou Baiyunshan Xing Zhu Pharmacentical Co., Ltd.

100 Translational Medicine associated with Guangzhou Baiyunshan Xing Zhu Pharmacentical Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 18 Jan 2026

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Guangzhou Baiyunshan Xing Zhu Pharmacentical Co., Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 18 Jan 2026

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing